Stay informed
Dropdown menu

TGCT CAN WRECK YOUR JOINT

TGCT

can Wreck

your joint

Living with tenosynovial giant cell tumor (TGCT) and experiencing pain, swelling, or stiffness? These are signs that inflammatory cells are working hard to cause destruction in your affected joints.1-3

LEARN MORE 
(no hard hat required)

THINGS ARE CHANGING IN TGCT

THINGS ARE CHANGING IN TGCT

Sign up now to hear more from us.

STAY INFORMED

The impact can be permanent

Let’s wreck the myth: just because TGCT isn’t cancer doesn’t mean it doesn’t have a profound physical and mental impact on people’s lives.1

Challenging symptoms1,4

The symptoms of TGCT can be burdensome and include pain, swelling, and joint stiffness.

Sneaky tumor growth1

TGCT can spread into the tissue and bone surrounding the joint and, if left untreated, may lead to permanent joint damage.

Build a strong foundation:

Talk to your care team about your priorities for treatment.

Treatment priorities may include:

  • Attempting to remove or shrink the tumor and reduce inflammation
  • Avoiding worsening symptoms
  • Improving pain and physical function

ONE COMMUNITY, MANY VOICES

Managing TGCT can impact daily life in many different ways.1,5

Answer a few questions and see the experiences of those in the TGCT community from a 2025 survey.

IN A STUDY OF 500 PEOPLE IN THE TGCT SUPPORT REGISTRY, THIS IS WHERE THEY WERE AFFECTED BY THE CONDITION.5

AMONG THE SAME 500 PEOPLE, THESE WERE THE SYMPTOMS THAT LED TO THEIR TGCT DIAGNOSIS.5

HERE'S HOW THE SAME 500 PEOPLE SAID TGCT AFFECTED THEM.5

REFERENCES

1. Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. doi:10.1016/j.ctrv.2022.102491. 2. Nishida Y, Tsukushi S, Nakashima H, et al. Osteochondral destruction in pigmented villonodular synovitis during the clinical course. J Rheum. 2012;39(2):345-351. doi:10.3899/jrheum.110730. 3. Spierenburg G, Staals EL, Palmerini E, et al. Active surveillance of diffuse-type tenosynovial giant cell tumors: a retrospective, multicenter cohort study. Eur J Surg Oncol. 2024;50(2):107953. doi:10.1016/j.ejso.2024.107953. 4. Stone WL, Basit H, Zubair M, Burns B. Pathology, inflammation. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. 5. Stern S, McKenzie PF, Bernthal N, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510. doi:10.1080/14796694.2025.2488635

YOU ARE NOW LEAVING TGCTWRECKS.COM

By clicking "Continue" below, you will be taken away from tgctwrecks.com to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit. You are solely responsible for your interactions with such websites.

CONTINUE TO SITE
RETURN TO TGCTWRECKS.COM
Divider desktop
Divider mobile

© 2026 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

SpringWorks Therapeutics, Inc. and EMD Serono, Inc. are Healthcare companies of Merck KGaA, Darmstadt, Germany.

This website is intended only for residents of the United States. Use and access of this site are subject to the terms and conditions set out in our Terms & Conditions and Privacy Policy.

US-NONOTGCT-00008 05/26